BACKGROUND: Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and CD8+ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. MATERIALS AND METHODS: We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. RESULTS: We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. CONCLUSIONS: Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer.
BACKGROUND: Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and CD8+ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. MATERIALS AND METHODS: We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. RESULTS: We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. CONCLUSIONS: Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer.
Entities:
Keywords:
Combination; Diacylglycerol Kinase; Drug Therapy; Immunotherapy; Programmed Cell Death-1; T Lymphocytes
Authors: A U Abeysekara; A Albert; R Alfaro; C Alvarez; J D Álvarez; R Arceo; J C Arteaga-Velázquez; D Avila Rojas; H A Ayala Solares; A S Barber; N Bautista-Elivar; A Becerril; E Belmont-Moreno; S Y BenZvi; D Berley; A Bernal; J Braun; C Brisbois; K S Caballero-Mora; T Capistrán; A Carramiñana; S Casanova; M Castillo; U Cotti; J Cotzomi; S Coutiño de León; C De León; E De la Fuente; B L Dingus; M A DuVernois; J C Díaz-Vélez; R W Ellsworth; K Engel; O Enríquez-Rivera; D W Fiorino; N Fraija; J A García-González; F Garfias; M Gerhardt; A González Muñoz; M M González; J A Goodman; Z Hampel-Arias; J P Harding; S Hernández; A Hernández-Almada; J Hinton; B Hona; C M Hui; P Hüntemeyer; A Iriarte; A Jardin-Blicq; V Joshi; S Kaufmann; D Kieda; A Lara; R J Lauer; W H Lee; D Lennarz; H León Vargas; J T Linnemann; A L Longinotti; G Luis Raya; R Luna-García; R López-Coto; K Malone; S S Marinelli; O Martinez; I Martinez-Castellanos; J Martínez-Castro; H Martínez-Huerta; J A Matthews; P Miranda-Romagnoli; E Moreno; M Mostafá; L Nellen; M Newbold; M U Nisa; R Noriega-Papaqui; R Pelayo; J Pretz; E G Pérez-Pérez; Z Ren; C D Rho; C Rivière; D Rosa-González; M Rosenberg; E Ruiz-Velasco; H Salazar; F Salesa Greus; A Sandoval; M Schneider; H Schoorlemmer; G Sinnis; A J Smith; R W Springer; P Surajbali; I Taboada; O Tibolla; K Tollefson; I Torres; T N Ukwatta; G Vianello; T Weisgarber; S Westerhoff; I G Wisher; J Wood; T Yapici; G Yodh; P W Younk; A Zepeda; H Zhou; F Guo; J Hahn; H Li; H Zhang Journal: Science Date: 2017-11-17 Impact factor: 47.728
Authors: Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg Journal: Blood Date: 2009-05-07 Impact factor: 22.113
Authors: Michael Quigley; Florencia Pereyra; Björn Nilsson; Filippos Porichis; Catia Fonseca; Quentin Eichbaum; Boris Julg; Jonathan L Jesneck; Kathleen Brosnahan; Sabrina Imam; Kate Russell; Ildiko Toth; Alicja Piechocka-Trocha; Douglas Dolfi; Jill Angelosanto; Alison Crawford; Haina Shin; Douglas S Kwon; Jennifer Zupkosky; Loise Francisco; Gordon J Freeman; E John Wherry; Daniel E Kaufmann; Bruce D Walker; Benjamin Ebert; W Nicholas Haining Journal: Nat Med Date: 2010-10-03 Impact factor: 53.440
Authors: Evan W Weber; Elena Sotillo; Rachel C Lynn; David Gennert; Peng Xu; Zinaida Good; Hima Anbunathan; John Lattin; Robert Jones; Victor Tieu; Surya Nagaraja; Jeffrey Granja; Charles F A de Bourcy; Robbie Majzner; Ansuman T Satpathy; Stephen R Quake; Michelle Monje; Howard Y Chang; Crystal L Mackall Journal: Nature Date: 2019-12-04 Impact factor: 49.962
Authors: Nikolaos Patsoukis; Jonathan S Duke-Cohan; Apoorvi Chaudhri; Halil-Ibrahim Aksoylar; Qi Wang; Asia Council; Anders Berg; Gordon J Freeman; Vassiliki A Boussiotis Journal: Commun Biol Date: 2020-03-17